1. Introduction {#s0005}
===============

Premature cardiovascular disease (CVD) is the leading cause of death in patients with kidney disease (CKD) \[[@bb0005], [@bb0010], [@bb0015]\], which is only partially explained by the effects of traditional CV risk factors and atherothrombotic coronary vascular complications. The non-atherosclerotic myocardial processes, which are intrinsically linked to marked structural and functional abnormalities include profound hypertrophic and interstitial remodeling and deposition of myocardial fibrosis \[[@bb0005]\], often referred to as 'uremic cardiomyopathy' \[[@bb0010]\]. Progression of CKD is associated with marked increase of risk of adverse events, including arrhythmia, sudden cardiac death and heart failure (HF) \[[@bb0010],[@bb0015]\]. Earlier recognition and timely management of structural myocardial changes represent essential steps towards improving the morbidity and mortality of CKD patients.

Aortic stiffness is an independent predictor of adverse CV events in numerous subpopulations with high CV risk including patients with CKD \[[@bb0020]\]. Markedly increased aortic stiffness is fundamentally an independent accelerator of pathophysiology; increased left ventricular (LV) afterload and wall stress induce hypertrophic response, extracellular matrix turnover and accumulation of diffuse myocardial fibrosis \[[@bb0025], [@bb0030], [@bb0035]\], decreasing the efficiency of aorto-ventricular interaction \[[@bb0040], [@bb0045], [@bb0050], [@bb0055]\]. Aortic stiffness is independently related with myocardial T1 mapping, an emerging non-invasive marker of diffuse myocardial fibrosis \[[@bb0060]\], and strong predictor of all cause and CV mortality and HF hospitalisation \[[@bb0065], [@bb0070], [@bb0075]\]. In this study, we examined the relationship between central pulse wave velocity (PWV) a measure of aortic stiffness and non-invasive imaging markers of diffuse fibrosis and LV remodeling, and their relationship with the presence and severity of CKD.

2. Methods {#s0010}
==========

This is a prospective observational study of consecutive CKD patients (*n* = 276) undergoing routine clinical assessment of cardiac function and structure, and presence of ischaemia by CMR ([NCT03749551](NCT03749551){#ir0005}). CKD was defined by estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease formula ≤60 ml/min/1.73 m^2^ \[[@bb0090],[@bb0095]\]. An independent age/gender/CV risk profile-matched cohort of patients with no evidence of kidney disease (eGFR ≫60 ml/min/1.73 m^2^ or other markers of kidney disease) served as control group (*n* = 242); these patients have been included in previous publications \[[@bb0065],[@bb0070]\]. Subjects with a known diagnosis of specific cardiomyopathy, either determined phenotypically by imaging, or by endomyocardial biopsy, including myocardial infiltration due to amyloidosis, iron accumulation, lipid-storage disease, hypertrophic or arrhythmogenic right ventricular cardiomyopathy, non-compaction cardiomyopathy) or significant (≥grade III) primary or secondary valvular heart disease, were excluded from this study (details in supplementary material). Clinical meta-data, including systolic/diastolic blood pressure (BP), body mass index (BMI), presence of traditional CV risk factors \[[@bb0100]\], NYHA class, symptoms, medication, and findings of transthoracic echocardiography (E/e′ mean) were recorded. Blood tests were performed on samples obtained prior to CMR using commercially available platforms. Exclusion criteria for all subjects were the generally accepted contraindications to CMR (implantable non-MR safe devices (*n* = 2), cerebral aneurysm clips (*n* = 0), cochlear implants (*n* = 1). All procedures were carried out in accordance with the Declaration of Helsinki (2013) and clinical management guidelines. All subjects were counselled on possible risks of nephrogenic systemic sclerosis (NSF) and the current state of the knowledge and formal recommendations for minimizing the risk of NSF prior to CMR \[[@bb0105],[@bb0110]\].The study protocol was reviewed and approved by the institutional ethics committee and written informed consent was obtained from all participants.

2.1. CMR image acquisition and analysis {#s0015}
---------------------------------------

All subjects underwent a routine clinical scan protocol using a 3-Tesla clinical scanner (Skyra, Siemens Healthineers, Erlangen, Germany) for cardiac volumes and function, native T1 mapping (using Frankfurt Main (FFM)-MOLLI sequence), ischaemia imaging, scar imaging by late gadolinium enhancement (LGE) and in-plane flow acquisition with high-temporal resolution. All sequence parameters were reported previously \[[@bb0055],[@bb0065]\], also included in supplementary material. Gadobutrol 0.1 mmol/kg (Gadovist®, Bayer, Leverkusen, Germany) was administered in all patients in line with the licensed recommendations for appropriate use of gadolinium-based contrast agents (GBCA) in diagnostic imaging \[[@bb0105],[@bb0110]\] for stress-myocardial perfusion using vasodilatory test (regadenosone iv. bolus 400 μg/5 ml) \[[@bb0115],[@bb0120]\]. Rest myocardial perfusion was omitted to minimize the total dose of GBCA \[[@bb0105],[@bb0110]\]. Assessment of cardiac volumes, function and mass, interpretation of myocardial perfusion and LGE images has been performed following standardized recommendations \[[@bb0125],[@bb0130]\]. LGE, an established marker of myocardial viability/hibernation with well-established prognostic significance, was characterized based on the presence and predominant pattern as ischaemic or non-ischaemic \[[@bb0125]\]. Central aortic PWV was calculated by dividing the length of the aorta between the locations used for aortic flow measurements with the time difference between the arrival of the pulse wave at these locations ([Fig. 1](#f0005){ref-type="fig"}). Relevant myocardial ischaemia was diagnosed by evidence of regional hypoperfusion affecting ≫10% myocardium (as 2 or more adjacent segments in 32 subsegment model) \[[@bb0115]\], whereas microvascular disease (MVD) was diagnosed as homogenous circumferential subendocardial hypoperfusion, lasting for over 6 consecutive beats, being often most pronounced in the midventricular slice. Inter- and intraobserver reproducibility and agreement of post-processing approaches have been reported previously \[[@bb0080],[@bb0085]\], data specific to the present cohort is included in the supplementary material.Fig. 1CMR imaging protocol, consisting of native T1 mapping, stress-myocardial perfusion for relevant myocardial ischaemia. Cine-imaging for cardiac volumes and LV mass, late gadolinium enhancement and PWV for central aortic stiffness. Rest myocardial perfusion was not performed in line with restricted allowance of GBCA in CKD \[[@bb0105],[@bb0110]\].Fig. 1

2.2. Statistical analysis {#s0020}
-------------------------

Statistical analysis was performed using SPSS software (SPSS Inc., Chicago, IL, USA, version 24.0). Departures from normality were examined using Shapiro-Wilk\'s test. Data is presented in counts (percentages), mean (standard deviation, SD) or median (interquartile range, IQR), as appropriate for the type of the data. Comparisons between groups were performed using Student *t*-test or one-way ANOVA for normally distributed variables, and chi2 and Mann-Whitney test for non-normally distributed variables. We used a modified CKD staging \[[@bb0090],[@bb0095]\], with Group 4 inclusive of all patients with eGFR ≪15 ml/min/1.73 m^2^. The associations were analyzed by uni- and multivariate linear regression analyses and compared by Fisher r-to-z transformation. Multivariate regression analyses were used to examine the predictive associations between aortic stiffness and myocardial imaging variables. Collinearity diagnostics used to examine the variance inflation factor analysis. All tests were two-tailed and *p*-value of ≪0.05 was considered statistically significant.

3. Results {#s0025}
==========

Characteristics of patient population are summarized in [Table 1](#t0005){ref-type="table"}. Controls and CKD-patients were similar for age, gender, CV risk profile and background clinical history. CKD patients had lower hemoglobin/hematocrit and higher eGFR, hs-tropT, C-reactive protein and NT-proBNP (*p* ≪ 0.05). The groups were similar for most cardiac medications, except for the higher proportion of aldosterone inhibitors in the non-CKD group, whereas loop diuretics were more commonly used in the CKD group (*p* ≪ 0.05 for all). Common causes of CKD included hypertension (including polycystic kidney disease, 114, 42%), diabetes (103, 38%) and vasculitis (57, 21%); in 106(39%) was cause multifactorial. Compared to controls, CKD-patients had higher LV volumes and mass, and lower global systolic function (LV -- ejection fraction, LV-EF, *p* ≪ 0.001). A third of all patients had LGE, with similar proportions for the presence and the pattern (ischaemic and non-ischaemic) between the groups. Non-ischaemic LGE was predominantly found as mid-myocardial septal striae (*n* = 24) followed by patchy diffuse intramyocardial LGE (*n* = 10). The mean extent of LGE (%) when present was similar between the groups, irrespectively of the LGE type ([Fig. 2](#f0010){ref-type="fig"}).Table 1Subjects\' characteristics. CMR measurements of function and structure and tissue characterization. Student *t*-test or Chi^2^ tests; all tests were two-tailed, *p* ≪ 0.05 was considered significant. BP -- blood pressure, CAD -- coronary artery disease, AF -- atrial fibrillation, eGFR -- estimated glomerular filtration rate, hs-TropT -- high sensitive troponin T, CRP - C-reactive protein, NT-proBNP -- N-terminal pro brain natriuretic peptide; RAS -- renin-angiotensin system, LV -- left ventricular, LGE -- late gadolinium enhancement.Table 1VariableNon-CKD controls (n = 242)CKD patients (n = 276)Sig. (*p*-value)Age (years)56 ± 1958 ± 210.131Male (n, %)145 (60)189(65)0.241BMI (kg/m^2^)27 ± 826 ± 90.185BP systolic (mm Hg)134 ± 17137 ± 210.077BP diastolic (mm Hg)79 ± 1078 ± 120.307Heart rate (bpm)73 ± 1375 ± 140.094Active smokers (n, %)48 (20)66 (24)0.274Past smokers (n, %)86 (35)88 (32)0.470Hypertension (n, %)192 (91)262 (95)0.073Diabetes (n, %)116 (48)143 (52)0.364 Type II (n, %)87 (36)112 (41)0.244Hyperlipidaemia (n, %)150 (62)188 (68)0.153Known CAD (n, %)68 (28)88 (32)0.3223-vessel CAD or equivalent (n, %)32 (13)48 (17)0.205Previous revascularisation (n, %)53 (22)77 (28)0.117Previous diagnosis of HF (n, %)77 (32)108 (39)0.097Known AF (n, %)29 (12)50 (18)0.058Blood hemoglobin (g/dl)14.2 ± 1.212.6 ± 1.4≪0.001Blood hematocrit (%)41.3 ± 5.239.8 ± 6.40.004eGFR (ml/min/m^2^)89 ± 1555 ± 25≪0.001hs C-reactive protein, mg/l3.9 ± 0.96.3 ± 1.8≪0.001hs-TropT (ng/l)6 (4--10)14 (6--30)0.013NT-proBNP (pg/l)78 (38--207)582 (187--2192)≪0.001 ≫300, n (%)46 (24)69 (62)≪0.001NYHA ≥III (n, %)68 (28)88 (32)0.322E/e′ (mean)8.3 ± 2.411.3 ± 4.5≪0.001  Cardiac medicationBeta blockers, n (%)138(57)174 (63)0.299RAS inhibitors, n (%)198(82)234(85)0.358Aldosterone inhibitors (n, %)68(28)33(12)≪0.001Neprilysin inhibitors (n, %)27(11)2(5)0.011Calcium antagonists (n, %)184(76)224(81)0.166Loop diuretics (n, %)68(28)199(72)≪0.001Platelet inhibition (n, %)138(57)136(51)0.172Statins (n, %)155(64)196(71)0.089  CMR measuresLV-EDV index, ml/m^2^83 ± 2093 ± 33\*≪0.001LV-ESV index, ml/m^2^36 ± 1946 ± 31\*≪0.001LV-EF,%58 ± 1154 ± 17\*≪0.001LV mass index, g/m^2^59 ± 1470 ± 19\*≪0.001RV-EF,%57 ± 956 ± 130.415LA area, cm^2^23 ± 527 ± 70.002Myocardial LGE, n (%)70(29)97(35)0.145Ischemic type, n (%)34(14)44(16)0.636Non-ischemic, n (%)36(15)53(19)0.366LGE extent,%4.9(0.2--3.8)5.7(2.5--8.9)0.083Myocardial ischaemia, n (%)27(11)44(16)0.098Microvascular disease, n (%)16(7)50(18)≪0.001Pericardial enhancement, n (%)8(3)11(4)0.539Pericardial effusion (≫1 cm), n (%)16(7)29(11)0.115Native T1, ms1123 ± 311152 ± 43≪0.001Central aortic PWV, m/s7.3 ± 2.49.2 ± 2.6≪0.001Fig. 2Aortic stiffness and diffuse myocardial fibrosis are negatively associated with severity of CKD. Bivariate associations between native T1 and PWV with eGFR (*r* = −0.31 and *r* = −0.44, *p* ≪ 0.001, respectively).Fig. 2

Patients with CKD had considerably higher myocardial native T1 and central aortic PWV (*p* ≪ 0.001), as well as abnormal diastolic relaxation by E/e′ (mean) by echocardiography (*p* ≪ 0.01). In the subgroup of controls with LGE, native T1 values and LV mass were higher and LV-EF was lower compared to those without LGE (native T1 (ms): 1138 ± 43 vs 1115 ± 37, LVmass (g/m^2^): 64 ± 14 vs 57 ± 13; LV-EF (%): 51 ± 13 vs 59 ± 8, *p* ≪ 0.001), whereas other parameters (PWV, E/e′, eGFR) did not differ. On the contrary, among CKD patients, native T1, PWV, E/e′ and LV mass were similar between patients with LGE and without, whereas LV-EF and eGFR were both markedly reduced in the former subgroup (LV-EF(%): 47 ± 16 vs. 59 ± 10; eGFR: 39 ± 16 vs. 33 ± 16, *p* ≪ 0.001).

3.1. Analysis of relationships {#s0030}
------------------------------

Group- (and CKD-stage-) specific associations with PWV are shown in [Table 2](#t0010){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}. There were significant association between PWV and age, NT-proBNP and native T1 in both groups. In the CKD group, there were also a significant association between PWV and eGFR, hematocrit and LV mass, global longitudinal strain and E/e′. Both groups showed significant associations between native T1 and measures of LV remodeling and stiffness. Furthermore, the associations between PWV and native T1, LV remodeling and stiffness were amplified in stages 3 and 4 ([Table 3](#t0015){ref-type="table"}, [Fig. 4](#f0020){ref-type="fig"}). Controlling for age, gender, BMI, systolic BP, CV risk factors, native T1 showed a stronger relationship with markers of structural and functional LV remodeling and diastolic impairment compared to PWV ([Table 4](#t0020){ref-type="table"}). In CKD group, dichotomizing for the presence and the type of LGE, the associations between PWV and native T1 were not significantly different (LGE-negative vs. LGE positive: *r* = 0.46 vs. *r* = 0.49, *p* ≪ 0.001, z-value −0.30, *p* = 0.763); ischemic vs non-ischemic LGE type: *r* = 0.44 vs. *r* = 0.53, *p* ≪ 0.001, z-value −0.56, *p* = 0.575. In multivariate stepwise linear regression analysis, accounting for CV risk factors and measures of LV remodeling, PWV was independently associated with native T1 in both groups (*p* ≪ 0.01); in CKD patients, this was followed by the model that also included eGFR (adjusted R^2^ = 0.28, *p* ≪ 0.01).Table 2Bivariate correlations of PWV and native T1 with subjects\' characteristics, LV geometry and function and tissue characterization. Pearson\'s (r, *p*-value) and Spearman (rho) coefficient, as appropriate for the type of the data. *p*-Value ≪0.05 was considered significant.Table 2VariableNon-CKD controlsCKD patientsPWV (m/s)Native T1 (ms)PWV (m/s)Native T1 (ms)Age (years)0.31(≪0.001)0.13(0.05)0.26(≪0.001)0.14(0.048)Gender (male)−0.06(0.35)0.10(0.17)0.16(0.006)0.10(0.11)Heart Rate (bpm)0.10(0.11)−0.06(0.39)0.012(0.84)0.05(0.45)BPsystolic (mm Hg)0.9(0.19)0.12(0.05)0.15(0.02)0.01(0.96)eGFR (ml/min/m^2^)0.06(0.38)0.04(0.38)−0.40(≪0.001)−0.32(≪0.001)Hematocrit (%)0.014(0.82)0.05(0.42)−0.21(0.002)−0.18(0.007)hs-TropT0.02(0.76)0.02(0.79)0.03(0.21)0.14(0.028)NT-proBNP0.14(0.03)0.25(≪0.001)−0.29(≪0.001)−0.30(≪0.001)PWV (m/s)/0.16(0.009)/0.47(≪0.001)Native T1 (ms)0.16(0.009)/0.47(≪0.001)/LV-EDVi, ml/m^2^0.20(≪0.001)0.24(≪0.001)0.10(0.09)0.29(≪0.001)LV-ESVi, ml/m^2^0.03(0.65)0.26 (≪0.001)0.09(0.13)0.33 (≪0.001)LV-EF (%)−0.061(0.33)−0.22(≪0.001)−0.16(0.069)−0.33(≪0.001)LV massi (g/m^2^)0.02(0.73)0.17(0.008)0.17(0.024)0.31(≪0.001)RV-EF (%)−0.10(0.611)−0.10(0.11)−0.023(0.31)−0.15(0.024)LA area, cm^2^0.11(0.113)0.21(0.006)0.24(0.002)0.23(0.001)E/e′ (mean)0.07(0.31)0.13(0.04)0.20(0.003)0.22(0.002)LGE (present)0.04(0.56)0.11 (0.112)0.02(0.83)0.19(0.005)LGE extent (%)0.09(0.37)0.11(0.06)0.03(0.23)0.07(0.19)Fig. 3Associations between aortic stiffness and markers of diffuse myocardial fibrosis, stiffness and remodeling are potentiated with severity of CKD. Bivariate correlations between PWV and native T1, E/e′ (mean), LV mass index and LV-EF.Fig. 3Table 3Pearson\'s associations between PWV and markers of LV remodeling increase with CKD stages. Comparisons are made against Stage 1 using r-to-z transformation (*p* ≪ 0.05\*, *p* ≪ 0.01\*\*).Table 3CKD stagesStage 1 ≫90 (*n* = 107)Stage 2 60--89 (*n* = 135)z-ValueStage 3 30--59 (*n* = 184)z-ValueStage 4 0--29 (*n* = 92)z-ValuePWV, m/s (r/rho)Native T10.10(0.32)0.27(0.002)1.40.31(≪0.001)2.3\*0.50(≪0.001)3.5\*\*E/e′ (mean)0.06(0.56)0.06(0.46)0.00.20(0.007)1.20.30(0.004)1.7\*LVmass (index)0.01(0.19)0.03(0.77)0.10.17(0.02)1.30.18(0.01)1.3LV-EF (%)−0.04(0.65)−0.13(0.13)0.7−0.15(0.051)1.0−0.17(0.03)1.1LGE (present)0.09(0.39)0.13(0.13)0.30.15(0.052)0.50.16(0.04)0.6Fig. 4Pulse wave velocity correlations and CKD Stages ([Table 3](#t0015){ref-type="table"}). Native T1 has the strongest association with PWV in all stages, followed by E/e′, LVmass in stage 3 and LV-EF in stage 4. \**p* ≪ 0.05, \*\**p* ≪ 0.01.Fig. 4Table 4Multivariate linear regression analysis of predictive associations with aortic stiffness (PWV).Table 4CKD patientsAdjusted R^2^B(95%CI)Sig. (*p*-value)VIFNative T1 (10 ms)0.280.2(0.15--0.25)≪0.0011.00All predictors in the model (*p*-value): age (0.22); gender (0.42), BMI (0.29), HTN (0.43), DM (0.62), smoking (0.22), hypercholesterolaemia (0.24), LV-EDV (0.13), LV-ESV (0.051); LV-EF (0.11), LV mass (0.06), E/e′ (mean) 0.013; LGE (presence) (0.25);  Non-CKD controlsAdjusted R^2^B(95%CI)Sig. (*p*-value)VIFNative T1 (10 ms)0.180.1(0.06--0.15)0.011.1All predictors in the model (*p*-value): age (0.39); gender (0.52), BMI (0.39), HTN (0.39), DM (0.32), smoking (0.61), hypercholesterolaemia (0.64); LV-EDV (0.62), LV-ESV (0.65); LV-EF (0.63), LV mass (0.93), LGE (presence) (0.91);

4. Discussion {#s0035}
=============

Our results provide important novel insights into the pathophysiology of CVD in CKD by underlining the strong associations between aortic stiffness and accelerated myocardial hypertrophic-fibrotic remodeling. In CKD group, aortic stiffness and markers of diffuse myocardial fibrosis, by PWV and native T1, respectively, were significantly higher and strongly associated with eGFR, whereas no such association were found in the non-CKD cohort despite similar CV risk profile. Aortic stiffness and native T1 were associated with measures of myocardial stiffness and structural remodeling; these associations were amplified with increasing severity of CKD. Native T1 was an independent associate of PWV in both groups, with considerably stronger predictive relationship in the CKD-group. Our findings suggest the pathophysiological commonality of adverse vasculo-ventricular remodeling, which is potentiated in the presence of CKD.

To the best of our knowledge, our study is the largest observational prospective study using in-depth and comprehensive characterization of CVD in CKD, providing novel pathophysiological insights that might shed light to the excess of CVD in CKD \[[@bb0010]\]. Several previous studies reported on T1 mapping in the CKD patients, generally revealing significantly higher values compared to controls, which were reproducible and unaffected by the fluid status \[[@bb0135],[@bb0140]\]. A further study in CKD highlighted the interrelatedness of T1 mapping markers with reduced LV-EF \[[@bb0145]\], which was not commensurate with the CV-risk factors. Our study expands on these previous observations by revealing strong associations between aortic stiffness, native T1 and markers of LV remodeling, all of which all have strong prognostic relevance in CKD patients \[[@bb0025],[@bb0030],[@bb0045], [@bb0050], [@bb0055],[@bb0065],[@bb0070],[@bb0150],[@bb0155]\]. Whereas native T1 was the independent associate of PWV in both groups, the predictive association was intensified in the presence of CKD.

The prominent role of native T1 suggests an essential pathophysiological connection with the excessive structural remodeling, functional impairment and consequently poor prognosis in CKD \[[@bb0015]\]. The association with aortic stiffness builds upon the established concept of aorto-ventricular interdependence, postulating myocardial injury as a consequence of the increased LV afterload \[[@bb0035],[@bb0055],[@bb0160], [@bb0165], [@bb0170], [@bb0175], [@bb0180], [@bb0185], [@bb0190], [@bb0195]\]. However, compared to myocardial hypertrophy within physiological range in non-CKD group \[[@bb0060],[@bb0200],[@bb0205]\], the marked structural remodeling in CKD is accompanied with myocardial diffuse fibrosis and dysfunction. In CKD, native T1 is higher at any given PWV implying potentiation of the adverse remodeling with worsening stages of CKD \[[@bb0050],[@bb0055],[@bb0210],[@bb0215]\] ([Fig. 3](#f0015){ref-type="fig"}). This effect appears inherently linked with the background presence of CKD likely related to neurohormonal overflow, which in addition to the chronic pressure and volume overload importantly accelerates LV remodeling with fibrosis, leading to development of HF \[[@bb0015],[@bb0180],[@bb0200],[@bb0220], [@bb0225], [@bb0230]\].

4.1. Limitations {#s0040}
----------------

A few technical notes are necessary. Owing to an on-going discussion on the technically optimal approach to quantify myocardial abnormalities with T1 mapping techniques, ranging from a wide spectrum of sequences, various possible confounders, such as, but not limited to, hematocrit, partial volume, motion, magnetization transfer and fast water exchange to postprocessing pathways allowing precision, as well as focus on diffuse disease by exclusion of LGE (summarized in \[[@bb0235], [@bb0240], [@bb0245]\]), the findings obtained with FFM-MOLLI sequence are not immediately transferable to other choices of T1 mapping sequences. Generally, native T1 mapping has several valuable advantages, which are technical (simple acquisition, high precision, interstudy reproducibility, transferability (multicentre data)), and clinical (high discrimination between health and disease, short clinical scans, contrast-free follow ups). As for any diagnostic test, standardization of data acquisition and postprocessing, as well as predefined reference ranges, are prerequisite for application of T1 mapping in clinical routine. We achieved this by unifying the imaging parameters, performing the on-the fly quality control and by using centralized postprocessing. In addition, we reduced confounding blood partial volume by placing the region of interest conservatively in septal myocardium of midventricular slice \[[@bb0185]\].

Native T1 using the present sequence and the postprocessing approach (i.e. excluding LGE) has the highest correlation with collagen volume fraction in a model of chronically elevated LV pressure (*r* = 0.58, *p* = 0.027), as such relatable to the conditions of the present study \[[@bb0060],[@bb0125]\] However, other important tissue influences, such as myocardial oedema, may have also been partially detected. Native T1 using this sequence/postprocessing approach also has a known relationship with outcome, which much stronger compared to ECV \[[@bb0065],[@bb0070]\]. Finally, this paper intends to inform specifically about relationship between native T1 and the aortic stiffness in the context of the presence and absence of CKD, and based on a standardized acquisition protocol and postprocessing \[[@bb0080],[@bb0085]\]. E/e′ mean measurements are known to be volume-load dependent and less reliable in patients with variable volume status, thus, may not be fully representative of diastolic impairment or increased LV loading pressures \[[@bb0225]\]. This is an ongoing study using standardized imaging protocols and data collection, which means that several subjects have been included in previous publications from our group \[[@bb0065],[@bb0070]\].

In conclusion, aortic stiffness and interstitial myocardial fibrosis are interrelated; this association is accelerated in the presence of CKD, but independent of LGE. Our findings reiterate the significant contribution of CKD-related factors to the pathophysiology of cardiovascular remodeling. Our findings provide important novel mechanistic insights into the pathophysiology of CVD in CKD, underlying the strong associations with between aortic stiffness and accelerated myocardial hypertrophic-fibrotic remodeling in this population. Future studies on the role of native T1 mapping in identification and prognostication and therapy of uremic cardiomyopathy are needed.
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